- Investing.com
Strategic Pipeline | Discover how EARLY TAVR and PROGRESS Trial initiatives aim to broaden treatment populations while five-year growth strategy emphasizes innovation and therapeutic development |
Analyst Outlook | Price targets range from $92 to $104, with firms maintaining Buy and Overweight ratings based on competitive positioning and indication expansion potential |
Clinical Validation | Seven-year PARTNER 3 data demonstrates TAVR matches surgical outcomes in structural valve deterioration and failure rates for younger, lower-risk patients |
Market Share Gains | Edwards Lifesciences positioned to capture 15-20% of competitor's TAVR market share amid Medtronic's challenges, mirroring historical Boston Scientific opportunity |
Metrics to compare | EW | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEWPeersSector | |
|---|---|---|---|---|
P/E Ratio | 48.7x | 27.1x | −0.4x | |
PEG Ratio | −0.67 | 0.01 | 0.00 | |
Price / Book | 5.1x | 2.3x | 2.6x | |
Price / LTM Sales | 8.3x | 2.5x | 3.0x | |
Upside (Analyst Target) | 9.5% | 76.0% | 51.9% | |
Fair Value Upside | Unlock | 17.1% | 9.1% | Unlock |
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.